Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 914 participants.

Also called NCT04950920

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 914 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04950920
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04950920. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-28 (actual); primary completion 2022-08-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke
Condition
Stroke
Intervention (Drug)
Y-2 sublingual tablets
Intervention (Drug)
d-borneol
Lead sponsor
Peking University Third Hospital (class: other)

Record details

Record id
cardio:ct-nct04950920
Content hash
0adfeb93bb3dd1bf001fda911468ff3d61124509ce82ff94f99e5eacc965deb6